Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
18 October 2023 | Story André Damons | Photo André Damons
Prof Mathys Labuschagne
Prof Chris Viljoen, Head of the School of Biomedical Sciences; Prof Gert van Zyl, Dean of the Faculty of Health Sciences; Prof Francis Petersen, UFS Vice-Chancellor and Principal; and Prof Mathys Labuschagne, Head of the Clinical Simulation and Skills Unit (CSSU), during the unit’s 10-year anniversary celebration.

In just 10 years, the Clinical Simulation and Skills Unit (CSSU) at the University of the Free State (UFS) went from being just a dream to becoming a national and international leader in medical simulation training.

The CSSU forms part of the School of Biomedical Sciences and was officially opened on 21 February 2013. The CSSU celebrated its 10-year anniversary on Thursday, 12 October 2023.

Prof Mathys Labuschagne, Head of the CSSU, said at the evening’s celebration that the vision and dream came true 10 years ago. “I think the requirement for the successful integration of simulation into a curriculum is first and foremost that it is based on research evidence. It is not a thumb-sucking exercise”.

“It is really seated in research and then you need passion and dedication. You cannot be successful without that, and for that I need to thank my staff – without your passion and dedication it would not be possible to excel,” said Prof Labuschagne.

Simulation important for patient safety

According to the professor, good networking is also important – between departments, professions and companies outside the university and hospital. He said simulation is important for improving patient safety and expanding the training platform.

“By doing simulation, we can train students who cannot always be accommodated on the training platform. There are also a lot of educational advantages to using simulation. Our training activities in the past 10 years grew tremendously. At the moment we have about 4000 undergraduate and postgraduate student contacts a year. Then we do a lot of certification and Continuing Professional Development (CPD) courses. During COVID-19 we did PPE training and ICU training for hospital and clinical staff in a safe environment.

“I am really proud of our research output. In the past 10 years we published 34 articles, and have another six articles currently in press. We have successfully completed eight master’s and seven PhD dissertations and there are now five students who are enrolled and all of them are simulation-associated. I cannot believe it has already been 10 years. I am very proud of the unit, and we strive for excellence in simulation education and training.”

Highlights of unit

Prof Gert van Zyl, Dean of the UFS Faculty of Health Sciences, congratulated the unit on achieving this milestone. Taking a trip down memory lane, he mentioned the names of colleagues who played a role in establishing the unit and said their contributions might not be visible in name in the unit, but they are recognised by them in achieving this milestone.

“It is an excellent achievement to have seven PhDs in 10 years. Well done. Another highlight is supporting the establishing of other simulation units at Nelson Mandela University who came to learn from us. They didn’t have to go the US. The training of staff and students during COVID-19, we had the facility. Let us not forget our simulation role at undergraduate and postgraduate training.

Cutting edge of simulation-based education and training

Prof Francis Petersen, UFS Vice-Chancellor and Principal, who gave a toast at the celebration, said the occasion is an opportunity to reflect on the excellent work done over the past decade and to consider how the unit is ideally placed to meet the aspirations that the UFS has for Vision 130 and the strategy of the university.

“The work of this unit has put the University of the Free State at the cutting edge of simulation-based education and training and the ongoing efforts of all of our staff in the unit who assist with the planning, the development, the setup, and the running of scenarios are acknowledged and greatly appreciated. I want to congratulate the leadership and the staff of the unit for the excellent work you are doing,” said Prof Petersen.

According to him, simulation education has numerous advantages such as improved patient safety, skills development, learning without involving real patients and the transfer of knowledge to the clinical environment. It creates a well-structured teaching and learning framework where simulation can be used as an educational tool assist in grasping the practical aspects of learning.

The training of specialised skills and deliberate practice are the key drivers behind clinical simulation as a training technique. It can also be applied as a tool to prepare students for a crisis situation, which requires high levels of preparedness and that is a very important aspect, said Prof Petersen.

“All these aspects of simulation-based education are something that relates very much to our vision and strategy. We want to be a research-led university, which means that it is not only doing research, but we try to focus on evidence and the research also helps us in the undergraduate programme to make it much more competitive.

“It also brings to the fore some qualities of our values, value of quality, value of impact and value of care. In addition, clinical simulation creates a vibrant learning experience for students and contributes towards our goal to meet the highest standards of excellence and impact in our teaching, learning and research.”

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept